• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Combined EGFR/ALK Expression Analysis in Laryngeal Squamous Cell Carcinoma.喉鳞状细胞癌中表皮生长因子受体/间变性淋巴瘤激酶联合表达分析
In Vivo. 2019 May-Jun;33(3):815-819. doi: 10.21873/invivo.11544.
2
Simultaneous over activation of EGFR, telomerase (h TERT), and cyclin D1 correlates with advanced disease in larynx squamous cell carcinoma: a tissue microarray analysis.EGFR、端粒酶（h TERT）和细胞周期蛋白 D1 的同时过度激活与喉鳞状细胞癌的晚期疾病相关：组织微阵列分析。
Med Oncol. 2011 Sep;28(3):871-7. doi: 10.1007/s12032-010-9522-3. Epub 2010 Apr 7.
3
MCM-2, Ki-67, and EGFR downregulated expression levels in advanced stage laryngeal squamous cell carcinoma.在晚期喉鳞状细胞癌中，MCM-2、Ki-67 和 EGFR 的表达水平下调。
Sci Rep. 2021 Jul 16;11(1):14607. doi: 10.1038/s41598-021-94077-9.
4
Laryngeal carcinoma lymph node metastasis and disease-free survival correlate with MASPIN nuclear expression but not with EGFR expression: a series of 108 cases.喉癌淋巴结转移和无病生存期与 MASPIN 核表达相关，而与 EGFR 表达无关：108 例系列研究。
Eur Arch Otorhinolaryngol. 2010 Jul;267(7):1103-10. doi: 10.1007/s00405-009-1186-2. Epub 2010 Jan 6.
5
A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy.ALK 阳性肺鳞癌研究：从诊断方法学到临床疗效。
Lung Cancer. 2019 Apr;130:135-142. doi: 10.1016/j.lungcan.2019.02.015. Epub 2019 Feb 18.
6
Retinoid X receptor overexpression desensitizes laryngeal epithelium to carcinogenic effects associated with epidermal growth factor receptor upregulation.维甲酸X受体过表达使喉上皮对与表皮生长因子受体上调相关的致癌作用产生脱敏。
J Otolaryngol Head Neck Surg. 2009 Apr;38(2):233-9.
7
Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer.ALK 基因拷贝数增加和扩增在非小细胞肺癌中很常见。
J Thorac Oncol. 2011 Jan;6(1):21-7. doi: 10.1097/JTO.0b013e3181fb7cd6.
8
Circular RNA ZNF609 promotes laryngeal squamous cell carcinoma progression by upregulating epidermal growth factor receptor via sponging microRNA-134-5p.环状 RNA ZNF609 通过海绵吸附 microRNA-134-5p 上调表皮生长因子受体促进喉鳞状细胞癌进展。
Bioengineered. 2022 Mar;13(3):6929-6941. doi: 10.1080/21655979.2022.2034703.
9
Zinc finger protein x-linked (ZFX) contributes to patient prognosis, cell proliferation and apoptosis in human laryngeal squamous cell carcinoma.X连锁锌指蛋白（ZFX）对人喉鳞状细胞癌患者的预后、细胞增殖和凋亡有影响。
Int J Clin Exp Pathol. 2015 Nov 1;8(11):13886-99. eCollection 2015.
10
Co-targeting ALK and EGFR parallel signaling in oral squamous cell carcinoma.在口腔鳞状细胞癌中共同靶向ALK和EGFR平行信号通路。
Oral Oncol. 2016 Aug;59:12-19. doi: 10.1016/j.oraloncology.2016.05.007.

引用本文的文献

1
Imipramine-induced Apoptosis and Metastasis Inhibition in Human Bladder Cancer T24 Cells Through EGFR/ERK/NF-κB Pathway Suppression.通过抑制EGFR/ERK/NF-κB通路，丙咪嗪诱导人膀胱癌T24细胞凋亡并抑制转移。
In Vivo. 2025 Mar-Apr;39(2):669-682. doi: 10.21873/invivo.13871.
2
Expression and clinical significance of programmed death ligand-1 evaluated by 22C3 antibody in pleural effusion metastatic non-small-cell lung cancer.22C3抗体评估程序性死亡配体-1在胸腔积液转移性非小细胞肺癌中的表达及临床意义
Cytojournal. 2024 Dec 20;21:70. doi: 10.25259/Cytojournal_59_2024. eCollection 2024.
3
Personalized Treatment Strategies via Integration of Gene Expression Biomarkers in Molecular Profiling of Laryngeal Cancer.通过整合基因表达生物标志物实现喉癌分子谱分析的个性化治疗策略
J Pers Med. 2024 Oct 10;14(10):1048. doi: 10.3390/jpm14101048.
4
Is precision medicine the solution to improve organ preservation in laryngeal/hypopharyngeal cancer? A position paper by the Preserve Research Group.精准医学是改善喉癌/下咽癌器官保存的解决方案吗？保存研究小组的立场文件。
Front Oncol. 2024 Aug 6;14:1433333. doi: 10.3389/fonc.2024.1433333. eCollection 2024.
5
DIAPH2 gene polymorphisms and laryngeal cancer risk in men.DIAPH2 基因多态性与男性喉癌风险。
J Cancer Res Clin Oncol. 2024 Jun 7;150(6):295. doi: 10.1007/s00432-024-05820-4.
6
ALK Protein Expression Patterns in Squamous Cell Carcinoma of the Oral Cavity.口腔鳞状细胞癌中 ALK 蛋白的表达模式。
In Vivo. 2022 May-Jun;36(3):1144-1149. doi: 10.21873/invivo.12813.
7
Overview on Molecular Biomarkers for Laryngeal Cancer: Looking for New Answers to an Old Problem.喉癌分子生物标志物概述：探寻一个老问题的新答案
Cancers (Basel). 2022 Mar 28;14(7):1716. doi: 10.3390/cancers14071716.
8
Impact of K-Ras Over-expression in Laryngeal Squamous Cell Carcinoma.K-Ras 过表达对喉鳞状细胞癌的影响。
In Vivo. 2021 May-Jun;35(3):1611-1615. doi: 10.21873/invivo.12418.

本文引用的文献

1
Induction of anaplastic lymphoma kinase (ALK) as a novel mechanism of EGFR inhibitor resistance in head and neck squamous cell carcinoma patient-derived models.诱导间变性淋巴瘤激酶（ALK）作为头颈部鳞状细胞癌患者衍生模型中表皮生长因子受体抑制剂耐药的新机制。
Cancer Biol Ther. 2018;19(10):921-933. doi: 10.1080/15384047.2018.1451285. Epub 2018 Aug 17.
2
High expression of c-Met and EGFR is associated with poor survival of patients with glottic laryngeal squamous cell carcinoma.c-Met和表皮生长因子受体（EGFR）的高表达与声门型喉鳞状细胞癌患者的不良生存相关。
Oncol Lett. 2018 Jan;15(1):931-939. doi: 10.3892/ol.2017.7356. Epub 2017 Nov 8.
3
Targeted Therapy and Imaging Findings.靶向治疗和影像学表现。
J Thorac Imaging. 2017 Sep;32(5):313-322. doi: 10.1097/RTI.0000000000000294.
4
Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor.个体化医学应对临床耐药：阿来替尼治疗第一代 ALK 抑制剂治疗后进展的 ALK 阳性非小细胞肺癌。
Clin Cancer Res. 2016 Nov 1;22(21):5177-5182. doi: 10.1158/1078-0432.CCR-16-1415. Epub 2016 Sep 8.
5
Co-targeting ALK and EGFR parallel signaling in oral squamous cell carcinoma.在口腔鳞状细胞癌中共同靶向ALK和EGFR平行信号通路。
Oral Oncol. 2016 Aug;59:12-19. doi: 10.1016/j.oraloncology.2016.05.007.
6
Absence of ALK and MET alterations in head and neck sarcomatoid carcinoma.
Oral Oncol. 2016 Jul;58:e4-5. doi: 10.1016/j.oraloncology.2016.05.015. Epub 2016 Jun 1.
7
The Dual Inhibition of Met and EGFR by ME22S, a Novel Met/EGFR Bispecific Monoclonal Antibody, Suppresses the Proliferation and Invasion of Laryngeal Cancer.新型Met/EGFR双特异性单克隆抗体ME22S对Met和EGFR的双重抑制作用可抑制喉癌的增殖和侵袭。
Ann Surg Oncol. 2016 Jun;23(6):2046-53. doi: 10.1245/s10434-015-5084-0. Epub 2016 Jan 26.
8
An update on clinicopathological, immunohistochemical, and molecular profiles of colloid carcinoma of the lung.肺黏液腺癌的临床病理、免疫组化及分子特征的最新进展
Hum Pathol. 2015 Jun;46(6):836-42. doi: 10.1016/j.humpath.2014.10.032. Epub 2015 Feb 20.
9
The landscape and therapeutic relevance of cancer-associated transcript fusions.癌症相关转录本融合的格局及其治疗相关性。
Oncogene. 2015 Sep 10;34(37):4845-54. doi: 10.1038/onc.2014.406. Epub 2014 Dec 15.
10
Epidermal growth factor receptor (EGFR) expression in patients with laryngeal squamous cell carcinoma.喉鳞状细胞癌患者表皮生长因子受体（EGFR）的表达
Eur Arch Otorhinolaryngol. 2015 Feb;272(2):401-5. doi: 10.1007/s00405-014-3323-9. Epub 2014 Oct 8.

喉鳞状细胞癌中表皮生长因子受体/间变性淋巴瘤激酶联合表达分析

Combined EGFR/ALK Expression Analysis in Laryngeal Squamous Cell Carcinoma.

作者信息

Politi Anastasia, Tsiambas Evangelos, Mastronikolis Nicholas S, Peschos Dimitrios, Asproudis Ioannis, Kyrodimos Efthymios, Armata Ilianna E, Chrysovergis Aristeidis, Asimakopoulos Asimakis, Papanikolaou Vasileios S, Batistatou Anna, Ragos Vasileios

机构信息

Department of Oncology, Medical School, University of Ioannina, Ioannina, Greece.

Department of IHC & Molecular Biology, 401 GAH, Athens, Greece

出版信息

In Vivo. 2019 May-Jun;33(3):815-819. doi: 10.21873/invivo.11544.

DOI:10.21873/invivo.11544
PMID:31028202
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6559894/
Abstract

BACKGROUND/AIM: Epidermal growth factor receptor (EGFR) acts as an oncogene in malignancies. Our aim was to examine the role of combined EGFR/ anaplastic lymphoma kinase (ALK) expression as molecular markers in laryngeal squamous cell carcinoma (LSCC) patients.

MATERIALS AND METHODS

Fifty (n=50) tissue sections derived from twenty-five (n=25) primary LSCCs were analyzed by immunohistochemistry (IHC).

RESULTS

EGFR overexpression was observed in 17/25 (68%) cases. Concerning ALK, 23/25 (92%) demonstrated low expression. EGFR expression was associated with grade (p=0.049), whereas ALK expression was correlated with stage (p=0.048). ALK overexpression was detected at advanced-stage EGFR-positive cases. A biphasic EGFR protein expression pattern was observed in five (n=5) LSCC cases, whereas ALK expression was stable in all cases.

CONCLUSION

EGFR overexpression is frequently observed in LSCC combined with low ALK expression. LSCC patients with EGFR/ALK protein overexpression should be eligible for targeted therapeutic strategies.

摘要

背景/目的：表皮生长因子受体（EGFR）在恶性肿瘤中作为一种癌基因发挥作用。我们的目的是研究EGFR/间变性淋巴瘤激酶（ALK）联合表达作为分子标志物在喉鳞状细胞癌（LSCC）患者中的作用。

材料与方法

通过免疫组织化学（IHC）分析了来自25例原发性LSCC的50个组织切片。

结果

在17/25（68%）的病例中观察到EGFR过表达。关于ALK，23/25（92%）表现为低表达。EGFR表达与分级相关（p=0.049），而ALK表达与分期相关（p=0.048）。在晚期EGFR阳性病例中检测到ALK过表达。在5例LSCC病例中观察到双相EGFR蛋白表达模式，而ALK表达在所有病例中均稳定。

结论

在LSCC中经常观察到EGFR过表达并伴有低ALK表达。EGFR/ALK蛋白过表达的LSCC患者应适合接受靶向治疗策略。